CG-0416 combined with a reduced-dose GLP-1 receptor agonist produced greater weight loss, and slower weight regain after the agonist was stopped SHANGHAI, Nov. 15, 2026 /PRNewswire/ -- In a poster at Obesity Week 2026, CureGene presented two preclinical studies of CG-0416, its oral,...
Hence then, the article about curegene presents two preclinical studies of cg 0416 at obesity week 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CureGene Presents Two Preclinical Studies of CG-0416 at Obesity Week 2026 )
Also on site :
- ‘Wild Horse Nine’ Star John Malkovich Is Back on Top, but 18 Years Ago, He Hit a Devastating Low in a Shocking Scandal
- Johnny Depp’s ‘Ebenezer’ Richer Abroad At $42M WW; ‘Ramayana’ Nears $150M WW; ‘Godzilla Minus Zero’ Roars Past $100M WW; ‘Wildwood’ $70M – Global Box Office
- Garbage Wraps 2026 Tour With Mariachi-Infused Free Show at Mexico City’s Zócalo: 5 Best Moments